文献速递骨质疏松与代谢性骨病小儿骨科

糖皮质激素替代治疗对骨密度真实世界影响:24年单中心CAH队列

Real-world impact of glucocorticoid replacement therapy on bone mineral density: retrospective experience of a large single-center CAH cohort spanning 24 years.
PubMed 文献 · Osteoporos Int · 2020-01-02

结果显示11%患者低骨密度,总髋Z评分在失盐型低于单纯男性化型,累积醋酸可的松与股骨颈Z评分负相关,而成年期地塞米松累积剂量与腰椎Z评分变化无关联。

要点

  • CAH成人低骨密度比例为11%,总髋Z评分失盐型低于单纯男性化型(p=0.04)。
  • 累积醋酸可的松剂量与股骨颈Z评分负相关(p<0.01)。
  • 地塞米松治疗期间累积剂量与腰椎Z评分变化无关联。

核心结论

  • 生长期间低醋酸可的松方案联合盐皮质激素替代可能影响股骨部位BMD,但成年期低剂量地塞米松似乎对骨健康无 deleterious 影响。

主要发现

  • 基于末次DXA,11%患者低骨密度,总髋Z评分失盐型低于单纯男性化型(p=0.04)。
  • 累积醋酸可的松剂量与股骨颈Z评分负相关(p<0.01)。
  • 总累积糖皮质激素和盐皮质激素剂量与总髋Z评分负相关(p<0.01)。
  • 地塞米松治疗期间,累积GC/MC剂量、临床型、性别与腰椎Z评分变化无关联。

关键数值与推荐

  • 低骨密度定义为基于末次DXA的观察结果,具体阈值未在摘要中报告。

临床怎么用

  • 对于CAH成人患者,应关注股骨部位骨密度,尤其是失盐型及累积醋酸可的松剂量较高者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The congenital adrenal hyperplasia population seems to have an intrinsic tendency to a high frequency of low bone mass. However in this single-center and long-term evaluated cohort, the simplified corticoid regimen, with exclusive dexamethasone single dose reposition during adulthood, did not represent a risk factor for decrease in bone health. INTRODUCTION: The impact of long-term and supposedly physiological doses of gluco and mineralocorticoid (GC/MC) on bone mineral density (BMD) in congenital adrenal hyperplasia (CAH) remains discordant among studies, which contain different clinical forms and corticoid regimens. Our aim was to evaluate the BMD in CAH adults receiving similar GC regimen since childhood and to correlate it with GC/MC cumulative doses. METHODS: Only patients with good compliance, who used cortisone acetate (CA) during childhood and dexamethasone after the final height achievement. Cumulative GC/MC doses were calculated from diagnosis until last evaluation. BMD was analyzed by the first and last energy X-ray absorptiometry (DXA) scans performed. RESULTS: Twenty simple virilizing (SV) and 14 salt wasting (WS) whose mean age was 26 ± 6 years, mean CA, dexamethasone, and fludrocortisone cumulative doses were 63,813 ± 32,767, 812 ± 558, and 319 ± 325 mg/m2, respectively. Based on the last DXA, low BMD was observed in 11% of patients, total hip Z-score was lower in the SW than SV form (p = 0.04). Cumulative CA dose had an inverse correlation with femoral neck Z-score (p < 0.01). Total cumulative GC and MC doses had an inverse correlation with total hip Z-score (p < 0.01). In the analysis of sequential BMD during dexamethasone therapy, no association was observed among cumulative GC/MC doses, clinical forms, sex, and lumbar Z-score delta. CONCLUSIONS: Even though a low CA regimen during growth periods in addition to MC replacement appears to have an influence on BMD at femoral sites, interestingly a low dexamethasone one does not seem to be deleterious for bone health in adulthood.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Iervolino LL, Ferraz-de-Souza B, Martin RM, et al. Real-world impact of glucocorticoid replacement therapy on bone mineral density: retrospective experience of a large single-center CAH cohort spanning 24 years. Osteoporos Int. 2020. PMID: 31897546. doi:10.1007/s00198-019-05268-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。